Indaptus Therapeutics, Inc. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024. Indaptus is a clinical-stage biotechnology company developing Decoy20, an investigational immunotherapy. It has no approved products and has not generated product revenue.
Financial results and liquidity
| Metric | Q1 2024 | Q1 2023 / prior date |
|---|---|---|
| Revenue | No product revenue | No product revenue |
| Research and development expense | $1.59 million | $1.88 million |
| General and administrative expense | $2.35 million | $2.58 million |
| Total operating expenses | $3.94 million | $4.46 million |
| Other income, net | $137,000 | $202,000 |
| Net loss | $3.81 million | $4.25 million |
| Basic and diluted loss per share | $0.45 | $0.51 |
| Cash used in operating activities | $3.94 million | $4.96 million |
| Cash and cash equivalents | $9.74 million | $13.36 million at Dec. 31, 2023 |
Operating expenses declined 11% year over year. R&D expense fell 15%, primarily because Decoy20 manufacturing activity had been higher in Q1 2023; G&A fell 9%, mainly due to lower legal, recruitment, and insurance costs. Management expects both expense categories to rise as clinical development advances. Gross margin and operating margin are not meaningful because the company has no product revenue.
At March 31, total current assets were $10.29 million and current liabilities were $1.54 million. Total liabilities were $1.59 million, primarily accounts payable, accrued liabilities, and operating lease obligations; the filing reports no material financing commitments such as credit lines. Lease liabilities totaled $153,000. The company used $3.94 million in operating cash and received $316,000 net from ATM share sales during the quarter. It sold 137,836 shares for approximately $0.3 million gross proceeds.
Business developments, outlook, and risks
- Decoy20 trial: The Phase 1 trial is an open-label dose-escalation and expansion study in patients with advanced solid tumors. The second single-dose cohort was completed in early March 2024; after Safety Review Committee authorization, the company advanced to the multi-dosing portion. The second-cohort dose was reduced based on the first cohort’s pharmacodynamic effects and the company’s expectations for safety in multi-dose and combination studies.
- Reported early safety observations: In the first cohort, four patients were evaluable. Reported events included transient changes in pulse or blood pressure, liver-enzyme elevations, and lymphocyte reductions. One patient experienced dose-limiting grade 3 bradycardia and grade 2 hypotension, which resolved with IV fluids. These early observations do not establish later-stage safety or efficacy.
- Runway and going concern: Management says the $9.74 million cash balance is expected to fund operations only through Q3 2024 under its current plan. The company states that substantial doubt exists about its ability to continue as a going concern and that it needs additional financing. It is pursuing potential collaborations, strategic alliances, or licensing arrangements and/or debt or equity financing, with no assurance of availability or acceptable terms. Insufficient funding could force reductions, delays, or termination of programs, or cessation of operations.
- Other risks: The business depends on successful clinical development, regulatory approval, third-party clinical and manufacturing providers, and future access to capital. Clinical outcomes, enrollment, manufacturing, adverse effects, competition, intellectual-property protection, reimbursement, and volatile capital markets could adversely affect prospects. Macroeconomic conditions may also hinder financing and operations.
- Other disclosures: No pending material legal proceedings were reported. Management concluded disclosure controls were effective at the reasonable-assurance level as of March 31, 2024; no material change in internal control over financial reporting was reported. No subsequent event requiring recognition or disclosure was identified through May 8, 2024.
Most important facts for investors to verify
- Whether the company secures financing or a collaboration before its stated Q3 2024 cash runway ends, and the resulting dilution or other terms.
- Progress, enrollment, dosing, safety findings, and any reported data from the Decoy20 multi-dosing Phase 1 trial.
- Actual quarterly cash burn relative to the $3.94 million operating cash use in Q1 and management’s runway assumptions.
- Remaining availability and restrictions under the ATM and Lincoln Park equity programs; no Lincoln Park shares had been sold as of the filing.
- Changes in clinical, regulatory, manufacturing, or other risks that could delay development or require additional capital.